Latest Breaking News On - Respirent pharmaceuticals - Page 1 : comparemela.com

10 Pharma Companies Making Treatment for Opioid Overdose

10 Pharma Companies Making Treatment for Opioid Overdose
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyNorth carolinaSpiriva handihalerRespirent pharmaceuticalsCenters for diseaseNational institute on drug abuseNumber of hedge fund holdersOpiant pharmaceuticals incAmneal pharmaceuticals incPharma companies making treatment for opioid overdosePfizer incServices incTitan pharmaceuticals incLannett company incBiodelivery sciences international inc

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRobert jaffeSpiriva handihalerLannett companyPrnewswire lannett company incBoehringer ingelheimDrug administrationCompany formRespirent pharmaceuticals coLannett company incRobert jaffe coTiotropium bromideRespirent pharmaceuticalsTim crewAbbreviated new drug applicationFluticasone propionate

Lannett (LCI) Soars 10 1%: Is Further Upside Left in the Stock?

Lannett (LCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Advair diskusRespirent pharmaceuticalsZacks investment researchZacks rankStrong buyZacks investmentTock price movementsTypical sessionStock priceஜாக்கக்ஸ் முதலீடு ஆராய்ச்சிஜாக்கக்ஸ் ரேங்க்வலுவான வாங்கஜாக்கக்ஸ் முதலீடு

Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing

Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing News provided by Share this article Share this article PHILADELPHIA, June 1, 2021 /PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg), which was submitted by Lannett on behalf of its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The FDA assigned a Generic Drug User Fee Act of 2017 (GDUFA II) goal date for this priority original ANDA of January 31, 2022. The product is the generic equivalent of ADVAIR DISKUS

United statesRobert jaffeAdvair diskusFlovent diskusLannett companyDrug administrationExchange commissionRespirent pharmaceuticals coLannett company incRobert jaffe coAbbreviated new drug applicationFluticasone propionateRespirent pharmaceuticalsGeneric drug user fee actTim crewFluticasone propionate powder inhaler